Reworked once-daily weight-loss pill from Pfizer to progress
![](/46/pdcnewsitem/12/49/00/Heading%20image%20(14).png)
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill.
Pfizer have announced their progression with a once-daily version of weight-loss drug danuglipron after ditching plans for a twice-daily version late last year. This drug product comes on the heels of other weight-loss drug products from the likes of Eli Lilly and Novo Nordisk, providing an oral alternative to injections.
The weight-loss drug market has been dominating in the last year, with both Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound estimated to bring in over US$150 billion in annual sales by 2030. While Pfizer have not released an exact timeline of danuglipron’s development, the company have stated their plans to evaluate multiple doses of the reformulated drug later this year before continuing to clinical trials. Earlier trials of the twice-daily version of danuglipron were halted after patients left midstage trials due to high rates of nausea and vomiting side effects. Pfizer have already scrapped their other weight-loss drug lotiglipron due to safety concerns regarding high levels of liver enzymes in some patients.
While concerns of side effects continue to caution analysts, Pfizer have stated that early study testing of a once-daily dose of danuglipron have shown no liver enzyme elevations in over 1400 healthy adult volunteers. Danuglipron is the latest in a line of GLP-1 agonists designed to mimic the action of GLP-1 hormones. This hormone regulates blood sugar levels, slows digestion, and suppresses appetite. Several companies such as Amgen and Viking Therapeutics have begun work on their own GLP-1 agonist drug products for next-generation weight-loss treatments.
Source:
Pfizer moves forward with once-daily weight-loss pill [Accessed July 12, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moves-forward-with-once-daily-weight-loss-drug-2024-07-11/
Related News
-
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance